Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
116.55
-2.09 (-1.76%)
Jan 31, 2025, 4:00 PM EST - Market closed
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for LGND stock have an average target of 145, with a low estimate of 135 and a high estimate of 160. The average target predicts an increase of 24.41% from the current stock price of 116.55.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 23, 2024.
Analyst Ratings
The average analyst rating for LGND stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +15.83% | Dec 23, 2024 |
| Barclays | Barclays | Buy Maintains $150 → $160 | Buy | Maintains | $150 → $160 | +37.28% | Dec 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $141 → $143 | Buy | Maintains | $141 → $143 | +22.69% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $130 → $140 | Buy | Maintains | $130 → $140 | +20.12% | Nov 12, 2024 |
Financial Forecast
Revenue This Year
166.59M
from 131.31M
Increased by 26.86%
Revenue Next Year
191.50M
from 166.59M
Increased by 14.95%
EPS This Year
5.74
from 2.94
Increased by 95.63%
EPS Next Year
6.07
from 5.74
Increased by 5.69%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 173.1M | 204.8M | 244.4M | |||
| Avg | 166.6M | 191.5M | 225.3M | |||
| Low | 158.5M | 165.4M | 203.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 31.8% | 22.9% | 27.6% | |||
| Avg | 26.9% | 15.0% | 17.7% | |||
| Low | 20.7% | -0.7% | 6.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 6.08 | 6.83 | 7.93 | |
| Avg | 5.74 | 6.07 | 7.00 | |
| Low | 5.22 | 4.67 | 5.71 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 107.1% | 18.8% | 30.6% | |
| Avg | 95.6% | 5.7% | 15.3% | |
| Low | 77.9% | -18.6% | -5.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.